AU2017339890A1 - Spirocyclic compounds - Google Patents
Spirocyclic compounds Download PDFInfo
- Publication number
- AU2017339890A1 AU2017339890A1 AU2017339890A AU2017339890A AU2017339890A1 AU 2017339890 A1 AU2017339890 A1 AU 2017339890A1 AU 2017339890 A AU2017339890 A AU 2017339890A AU 2017339890 A AU2017339890 A AU 2017339890A AU 2017339890 A1 AU2017339890 A1 AU 2017339890A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cancer
- pharmaceutically acceptable
- acceptable salt
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C(*)(C(N(CC1)CCC1C1=SC(c2n[n](*)cn2)=C*1)=O)N(CC1)CC1(CCN1c2ccc3[n]nc(*)c3n2)C1=O Chemical compound *C(*)(C(N(CC1)CCC1C1=SC(c2n[n](*)cn2)=C*1)=O)N(CC1)CC1(CCN1c2ccc3[n]nc(*)c3n2)C1=O 0.000 description 4
- QFAFHGFHTWCMLA-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(ncc(OC)c2)c2F)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(ncc(OC)c2)c2F)=N)c1N QFAFHGFHTWCMLA-AREMUKBSSA-N 0.000 description 2
- KKQWWWRULKAZMS-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC)=N)c1N KKQWWWRULKAZMS-MUUNZHRXSA-N 0.000 description 2
- NOSJWUFHNGRUEZ-UHFFFAOYSA-N CC(C)N(C=C(C=C1)S)C1=O Chemical compound CC(C)N(C=C(C=C1)S)C1=O NOSJWUFHNGRUEZ-UHFFFAOYSA-N 0.000 description 1
- AFBCCSUDEYRUOH-BDPMCISCSA-N CCN(C([C@H](CC1)CN1C(C)C(N(CC1)CC=C1c1ncc(-c2n[nH]cn2)[s]1)=O)=O)c(cc1)nc(C(c(cn2)ccc2O)=N)c1N Chemical compound CCN(C([C@H](CC1)CN1C(C)C(N(CC1)CC=C1c1ncc(-c2n[nH]cn2)[s]1)=O)=O)c(cc1)nc(C(c(cn2)ccc2O)=N)c1N AFBCCSUDEYRUOH-BDPMCISCSA-N 0.000 description 1
- SEWNOFLJMIVUNA-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2c[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2O)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2c[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2O)=N)c1N SEWNOFLJMIVUNA-HHHXNRCGSA-N 0.000 description 1
- BZRRJXJSPVJJHA-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(nc(cc2)OC)c2F)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(nc(cc2)OC)c2F)=N)c1N BZRRJXJSPVJJHA-AREMUKBSSA-N 0.000 description 1
- PGSFOUYHAMEIRR-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(nc2)ccc2OC)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(nc2)ccc2OC)=N)c1N PGSFOUYHAMEIRR-HHHXNRCGSA-N 0.000 description 1
- AOASPQUJMBDGKS-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(ncc(OC(C)C)c2)c2F)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(ncc(OC(C)C)c2)c2F)=N)c1N AOASPQUJMBDGKS-MUUNZHRXSA-N 0.000 description 1
- LJMFDIJOCNEPFB-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c2cccc(OC)n2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c2cccc(OC)n2)=N)c1N LJMFDIJOCNEPFB-HHHXNRCGSA-N 0.000 description 1
- XNPWEZNWDRGCRW-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2C#N)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2C#N)=N)c1N XNPWEZNWDRGCRW-GDLZYMKVSA-N 0.000 description 1
- XICWZEYZNCRXTN-RUZDIDTESA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(ccc(Cl)c2)c2F)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(ccc(Cl)c2)c2F)=N)c1N XICWZEYZNCRXTN-RUZDIDTESA-N 0.000 description 1
- BSVPMNWPUCAPQO-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2OC2CC2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2OC2CC2)=N)c1N BSVPMNWPUCAPQO-MUUNZHRXSA-N 0.000 description 1
- OYGZNVVTCCWEGG-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(nc2)ccc2C#N)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(nc2)ccc2C#N)=N)c1N OYGZNVVTCCWEGG-HHHXNRCGSA-N 0.000 description 1
- DAVNEMMUXHXOKF-RUZDIDTESA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(nc2)ccc2F)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(nc2)ccc2F)=N)c1N DAVNEMMUXHXOKF-RUZDIDTESA-N 0.000 description 1
- AEMHCASSGAUBLD-RUZDIDTESA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c2c[n](C)nc2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c2c[n](C)nc2)=N)c1N AEMHCASSGAUBLD-RUZDIDTESA-N 0.000 description 1
- HYYUOAQFZWABSS-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c2ccc(C)cc2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c2ccc(C)cc2)=N)c1N HYYUOAQFZWABSS-GDLZYMKVSA-N 0.000 description 1
- UAUHLMHIGBMSDB-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c2cnc(C)cc2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c2cnc(C)cc2)=N)c1N UAUHLMHIGBMSDB-MUUNZHRXSA-N 0.000 description 1
- KSSDOHWRFNMWFU-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(OC(NC)=O)=N)=O)CC1)=O)c(cc1)cc(C(N2CCOCC2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(OC(NC)=O)=N)=O)CC1)=O)c(cc1)cc(C(N2CCOCC2)=N)c1N KSSDOHWRFNMWFU-AREMUKBSSA-N 0.000 description 1
- GKIVQZBBKPGFKE-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2I)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2I)=N)c1N GKIVQZBBKPGFKE-AREMUKBSSA-N 0.000 description 1
- ABGLSANAHSYHDN-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2O)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2O)=N)c1N ABGLSANAHSYHDN-AREMUKBSSA-N 0.000 description 1
- RCHSFXFQSCODQD-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2OC(C)C)=N)c1N RCHSFXFQSCODQD-GDLZYMKVSA-N 0.000 description 1
- YTKIZJCGOGFUNW-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2OC)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCC2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cn2)ccc2OC)=N)c1N YTKIZJCGOGFUNW-HHHXNRCGSA-N 0.000 description 1
- RROYUGZFYVFTGJ-XMMPIXPASA-N CCN(C([C@H]1CN(CC(N(CC2)CCN2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(nc2)ccc2F)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCN2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(nc2)ccc2F)=N)c1N RROYUGZFYVFTGJ-XMMPIXPASA-N 0.000 description 1
- BUARDDXLKZUHLB-GFCCVEGCSA-N CCN(C([C@H]1CNCC1)=O)c(cc1)nc(C(c(cn2)ccc2I)=N)c1N Chemical compound CCN(C([C@H]1CNCC1)=O)c(cc1)nc(C(c(cn2)ccc2I)=N)c1N BUARDDXLKZUHLB-GFCCVEGCSA-N 0.000 description 1
- VPUGRYVFLVSMEK-HXUWFJFHSA-N CCNC([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O Chemical compound CCNC([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O VPUGRYVFLVSMEK-HXUWFJFHSA-N 0.000 description 1
- BPHRIAQKFXNEIJ-OAHLLOKOSA-N CCNC([C@H]1CN(CC(N(CC2)CC=C2c2ncc(-c3n[n](C)cn3)[s]2)=O)CC1)=O Chemical compound CCNC([C@H]1CN(CC(N(CC2)CC=C2c2ncc(-c3n[n](C)cn3)[s]2)=O)CC1)=O BPHRIAQKFXNEIJ-OAHLLOKOSA-N 0.000 description 1
- WBEOAPVJQYPMJX-UHFFFAOYSA-N C[n]1nc(-c2ccc(C(CC3)=CCN3C(CCl)=O)[s]2)nc1 Chemical compound C[n]1nc(-c2ccc(C(CC3)=CCN3C(CCl)=O)[s]2)nc1 WBEOAPVJQYPMJX-UHFFFAOYSA-N 0.000 description 1
- RRQVAFHXHIGPCY-UHFFFAOYSA-N Cc(cc1)cc(C(c(nc2)ccc2C#N)=N)c1N Chemical compound Cc(cc1)cc(C(c(nc2)ccc2C#N)=N)c1N RRQVAFHXHIGPCY-UHFFFAOYSA-N 0.000 description 1
- HCKSKBWVHAOXNH-UHFFFAOYSA-N Cc(cc1)cc(C(c2ccc(C)nc2)=N)c1N Chemical compound Cc(cc1)cc(C(c2ccc(C)nc2)=N)c1N HCKSKBWVHAOXNH-UHFFFAOYSA-N 0.000 description 1
- CMHOPXZCABRXMU-UHFFFAOYSA-N O=C(CCl)N(CC1)CC=C1c(cc1)cc(F)c1-c1n[nH]cn1 Chemical compound O=C(CCl)N(CC1)CC=C1c(cc1)cc(F)c1-c1n[nH]cn1 CMHOPXZCABRXMU-UHFFFAOYSA-N 0.000 description 1
- HMIGUMSOMCLEFT-FQEVSTJZSA-N O=C([C@@]1(CC2)CNCC1)N2c(cc1)cc(c(-c(cc2)ccc2F)n2)c1[n]2I Chemical compound O=C([C@@]1(CC2)CNCC1)N2c(cc1)cc(c(-c(cc2)ccc2F)n2)c1[n]2I HMIGUMSOMCLEFT-FQEVSTJZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| US62/404,668 | 2016-10-05 | ||
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017339890A1 true AU2017339890A1 (en) | 2019-04-11 |
Family
ID=61831517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017339890A Abandoned AU2017339890A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (https=) |
| EP (1) | EP3523306A4 (https=) |
| JP (2) | JP6949952B2 (https=) |
| KR (1) | KR20190075931A (https=) |
| CN (1) | CN109890827A (https=) |
| AU (1) | AU2017339890A1 (https=) |
| BR (1) | BR112019005305A2 (https=) |
| CA (1) | CA3037064A1 (https=) |
| IL (1) | IL265752A (https=) |
| MX (1) | MX2019003938A (https=) |
| RU (1) | RU2019107667A (https=) |
| TW (1) | TW201817732A (https=) |
| WO (1) | WO2018067512A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| HUE049481T2 (hu) | 2015-04-03 | 2020-09-28 | Recurium Ip Holdings Llc | Spirociklusos vegyületek |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| IL281212B2 (en) * | 2018-09-07 | 2023-12-01 | Merck Patent Gmbh | 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) * | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2025096858A1 (en) * | 2023-10-31 | 2025-05-08 | C4 Therapeutics, Inc. | Compounds for the degradation of mutant braf |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3305776T (lt) * | 2004-05-14 | 2020-01-10 | Vertex Pharmaceuticals Incorporated | Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais |
| HRP20110892T1 (hr) * | 2005-12-13 | 2011-12-31 | Schering Corporation | Policiklični derivati indazola koji su inhibitori erk |
| WO2008063609A2 (en) | 2006-11-17 | 2008-05-29 | Polyera Corporation | Diimide-based semiconductor materials and methods of preparing and using the same |
| WO2008156739A1 (en) * | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| US20110166124A1 (en) | 2008-07-23 | 2011-07-07 | Mccormick Kevin D | Tricyclic spirocycle derivatives and methods of use |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| ES2609579T3 (es) * | 2011-08-29 | 2017-04-21 | VIIV Healthcare UK (No.5) Limited | Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| KR102243637B1 (ko) | 2013-03-14 | 2021-04-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 진통 화합물 |
| WO2016106009A1 (en) | 2014-12-22 | 2016-06-30 | Eli Lilly And Company | Erk inhibitors |
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| HUE049481T2 (hu) | 2015-04-03 | 2020-09-28 | Recurium Ip Holdings Llc | Spirociklusos vegyületek |
-
2017
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109890827A (zh) | 2019-06-14 |
| JP6949952B2 (ja) | 2021-10-13 |
| US10934304B2 (en) | 2021-03-02 |
| BR112019005305A2 (pt) | 2019-07-02 |
| JP2019534261A (ja) | 2019-11-28 |
| WO2018067512A1 (en) | 2018-04-12 |
| TW201817732A (zh) | 2018-05-16 |
| MX2019003938A (es) | 2019-06-10 |
| US20210115058A1 (en) | 2021-04-22 |
| CA3037064A1 (en) | 2018-04-12 |
| RU2019107667A (ru) | 2020-11-06 |
| KR20190075931A (ko) | 2019-07-01 |
| WO2018067512A8 (en) | 2018-11-01 |
| US20200207776A1 (en) | 2020-07-02 |
| EP3523306A1 (en) | 2019-08-14 |
| RU2019107667A3 (https=) | 2021-01-27 |
| NZ751398A (en) | 2021-03-26 |
| JP2021193138A (ja) | 2021-12-23 |
| EP3523306A4 (en) | 2020-05-06 |
| IL265752A (en) | 2019-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10934304B2 (en) | Spirocyclic compounds | |
| US12264149B2 (en) | Indazole compounds as kinase inhibitors | |
| EP4306529B1 (en) | Fgfr inhibitors and methods of use thereof | |
| KR102645995B1 (ko) | Rsv 억제제로서의 병용 약학 제제 | |
| US10493060B2 (en) | Spirocyclic compounds | |
| JP2017529373A (ja) | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 | |
| KR20210153051A (ko) | 매크로사이클릭 화합물 | |
| NZ751398B2 (en) | Spirocyclic compounds | |
| HK1256671B (en) | Spirocyclic compounds | |
| EA050408B1 (ru) | Соединение индазола в качестве ингибиторов киназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: RECURIUM IP HOLDINGS, LLC Free format text: FORMER NAME(S): ZENO ROYALTIES & MILESTONES, LLC |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |